CSL Reports Profits Up 63 Percent for FY 2009; Swine Flu Data Expected Next Month
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered CSL reported this week that it posted AU$1.15 billion ($943 million) in net profits for FY2009, up 63 percent year on year. With cash flow from operations of AU$1.03 billion, the company is well positioned for an alternative acquisition target after scuttling its $3.1 billion merger with U.S.-based Talecris